Safety and efficacy of single-agent docetaxel (Taxotere) administered weekly in non-small cell lung carcinoma patients in Korea: An observational study
- Authors
- Lim, Sun Min; Park, Byeong Bae; Park, Keun-Chil; Kim, Hoon-Kyo; Lee, Jong Seok; Bae, Sung Hwa; Lee, Seung-Sei; Kang, Jin-Hyoung; Park, Se-Hoon; Lee, Gyeong-Won; Lee, Hyo-Rac; Seo, Jae Hong; Kim, Yong Tae; Yang, Sung Hyun; Kim, Joo-Hang
- Issue Date
- 3월-2016
- Publisher
- WILEY-BLACKWELL
- Keywords
- Carcinoma; docetaxel; non-small cell lung cancer; safety
- Citation
- THORACIC CANCER, v.7, no.2, pp.207 - 214
- Indexed
- SCIE
SCOPUS
- Journal Title
- THORACIC CANCER
- Volume
- 7
- Number
- 2
- Start Page
- 207
- End Page
- 214
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/89354
- DOI
- 10.1111/1759-7714.12315
- ISSN
- 1759-7706
- Abstract
- BackgroundTo investigate the efficacy, safety, and tolerability of weekly docetaxel treatment in advanced non-small cell lung cancer (NSCLC) patients in Korea. MethodsThis prospective observational study included Korean advanced NSCLC patients with Eastern Cooperative Oncology Group performance status <2 who received weekly monotherapy of docetaxel at a dose determined by the physician. Efficacy measurements included tumor response rate, overall survival (OS), progression-free survival, and one-year survival rate. Safety was analyzed through recorded incidences of adverse events (AEs), serious adverse events (SAEs), deaths, and other related safety parameters, along with their toxicity grades. Results:Of 274 patients analyzed, one patient achieved a complete response and 42 partial responses; thus, the overall response rate was 15.7%. The OS rate at baseline and at one-year follow-up was 38.3% and 33.8%, respectively. AEs were reported in 229 (83.6%) patients. The most frequently reported hematologic AE of grade 3 was a decrease in neutrophils, with 6.6% of the patients developing neutropenia. In non-hematologic AEs of grade 3, the most common were infection with unknown absolute neutrophil count and death not associated with Common Terminology Criteria for Adverse Events (CTCAE) (4.7% each). The most common SAE reported was death, not associated with CTCAE (7.3%). ConclusionsIn Korean patients, the weekly regimen of docetaxel monotherapy was safe and efficacious against advanced NSCLC.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.